Antibodies to the epidermal growth factor receptor block the biological activities of sarcoma growth factor.

AUTOR(ES)

Carpenter, G

RESUMO

The role of the epidermal growth factor (EGF) receptor system in mediating the biological activities of sarcoma growth factor (SGF) has been assessed by using specific anti-EGF receptor antibodies. There are two classes of anti-EGF receptor antibodies, those that block binding of 125I-labeled EGF (125I-EGF) and those that do not block binding but do interact with a portion of the EGF receptor on the surface of intact cells. Antisera of both types have been assayed for their capacity to affect the biological activities of SGF. The antisera that block 125I-EGF binding to its receptor block the induction of DNA synthesis in human fibroblasts by either EGF or SGF but not by other polypeptide mitogens. Titration of the anti-EGF receptor antiserum indicates the presence of one population of antibody that blocks the site of both EGF and SGF action. Antisera to the EGF receptor that block 125I-EGF binding also inhibited the SGF-dependent anchorage-independent growth of normal cells in soft agar. The antisera to the EGF receptor that does not block 125I-EGF binding or EGF activity did not inhibit any of the biological activities of SGF. The results suggest that occupation of the EGF receptor is required for both the mitogenic and colony-forming activity of SGF.

Documentos Relacionados

• Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor.
• Human epidermal growth factor receptor residue covalently cross-linked to epidermal growth factor.
• Direct identification of residues of the epidermal growth factor receptor in close proximity to the amino terminus of bound epidermal growth factor.
• Biological and biochemical activities of a chimeric epidermal growth factor-Elk receptor tyrosine kinase.
• Tumor promoters block tyrosine-specific phosphorylation of the epidermal growth factor receptor.